EGFR Analysis in Cytologic Samples of Lung Adenocarcinoma by Microdissection
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The discovery of activating mutations in EGFR in a subset of lung adenocarcinomas was a major advance in our understanding of lung adenocarcinoma biology, and has led to groundbreaking studies that have demonstrated the efficacy of tyrosine kinase inhibitor therapy. Cytologic specimen procedures have become increasingly popular for obtaining diagnostic material in lung carcinomas. However, frequently the small amount of material or sparseness of tumor cells obtained from cytologic preparations limit the number of specialized studies, such as mutation analysis, that can be performed. In this study we used microdissection to isolate small numbers of tumor cells to assess for EGFR mutations from 76 cytological smear slides of patients with lung adenocarcinomas. We compared our results with previous molecular assays that had been performed on either surgical or cytology specimens as part of the patient’s initial clinical work-up. Not only were we able to detect the identical EGFR mutation through the pyrosequencing, but we were also able to consistently detect the mutation from as few as 25 microdissected tumor cells. Furthermore, isolating a purer population of tumor cells resulted in increased sensitivity of mutation detection as we were able to detect mutations from microdissection-enriched cases. Therefore, microdissection can not only significantly increase the number of lung adenocarcinoma patients that can be screened for EGFR mutations, but can also facilitate the use of cytologic samples in the newly emerging field of molecular-based personalized therapies.
Abstract
The discovery of activating mutations in EGFR in a subset of lung adenocarcinomas was a major advance in our understanding of lung adenocarcinoma biology, and has led to groundbreaking studies that have demonstrated the efficacy of tyrosine kinase inhibitor therapy. Cytologic specimen procedures have become increasingly popular for obtaining diagnostic material in lung carcinomas. However, frequently the small amount of material or sparseness of tumor cells obtained from cytologic preparations limit the number of specialized studies, such as mutation analysis, that can be performed. In this study we used microdissection to isolate small numbers of tumor cells to assess for EGFR mutations from 76 cytological smear slides of patients with lung adenocarcinomas. We compared our results with previous molecular assays that had been performed on either surgical or cytology specimens as part of the patient’s initial clinical work-up. Not only were we able to detect the identical EGFR mutation through the pyrosequencing, but we were also able to consistently detect the mutation from as few as 25 microdissected tumor cells. Furthermore, isolating a purer population of tumor cells resulted in increased sensitivity of mutation detection as we were able to detect mutations from microdissection-enriched cases. Therefore, microdissection can not only significantly increase the number of lung adenocarcinoma patients that can be screened for EGFR mutations, but can also facilitate the use of cytologic samples in the newly emerging field of molecular-based personalized therapies.
참고문헌 (30)
- Asano H, "Detection of EGFR gene mutation in lung cancer by mutant enriched polymerase chain reaction assay", Clin Cancer Res, 12, pp.43~48 (2006)
- Boldrini L, "Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis", J Thorac Oncol, 2, pp.1086~1090 (2007)
- Clark DP, "Seize the opportunity: underutilization of fine-needle aspiration biopsy to inform targeted cancer therapy decisions", Cancer Cytopathol, 117, pp.289~297 (2009)
- Eberhard DA, "Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib", J Clin Oncol, 23, pp.5900~5909 (2005)
- El-Serag HB, "Gene expression in Barrett’s esophagus: laser capture versus whole tissue", Scand J Gastroenterol, 44, pp.787~795 (2009)
- Emmert-Buck MR, "Laser capture microdissection", Science, 274, pp.998~1001 (1996)
- Fend F, "Laser capture microdissection in pathology", J Clin Pathol, 53, pp.666~672 (2000)
- Han SW, "Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib", J Clin Oncol, 23, pp.2493~2501 (2005)
- Harrell JC, "Contaminating cells alter gene signatures in whole organ versus laser capture microdissected tumors: a comparison of experimental breast cancers and their lymph node metastases", Clin Exp Metastasis, 25, pp.81~88 (2008)
- 황태숙, "Molecular Biologic Techniques in Cytopathologic Diagnosis", Journal of Pathology and Translational Medicine, 43(5), pp.387~392 (2009), 대한병리학회
- Jackman DM, "Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non small cell lung cancer patients: results of an online tumor registry of clinical trials", Clin Cancer Res, 15, pp.5267~5273 (2009)
- Janne PA, "A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening", Clin Cancer Res, 12, pp.751~758 (2006)
- Kim HJ, "Clinical investigation of EGFR mutation detection by pyrosequencing in lung cancer patients", Oncology letters, 5, pp.271~276 (2013)
- Lynch TJ, "Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib", N Engl J Med, 350, pp.2129~2139 (2004)
- Marchetti A, "Assessing EGFR mutations", N Engl J Med, 354, pp.526~528 (2006)
- Mok TS, "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma", N Engl J Med, 361, pp.947~957 (2009)
- 오서영, "Improved DNA Extraction Method for Molecular Diagnosis from Smaller numbers of Cells", 대한임상검사과학회지, 46(3), pp.99~105 (2014), 대한임상검사과학회[DOI]
- 오서영, "BRAF V600E 돌연변이 검사를 위한 Pyrosequencing 분석법 평가", 대한임상검사과학회지, 47(1), pp.17~23 (2015), 대한임상검사과학회[DOI]
- Paez JG, "EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy", Science, 304, pp.1497~1500 (2004)
- Pao W, "EGF receptor gene mutations are common in lung cancers from ‘‘never smokers’’ and are associated with sensitivity of tumors to gefitinib and erlotinib", Proc Natl Acad Sci, 101, pp.13306~13311 (2004)
- Quach N, "In vitro mutation artifacts after formalin fixation and error prone translesion synthesis during PCR", BMC Clin Pathol, 4(1) (2004)
- Rivera MP, "Diagnosis of lung cancer:the guidelines", Chest, 123, pp.129S~136S (2003)
- Rosell R, "Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway", Clin Cancer Res, 12, pp.7222~7231 (2006)
- Smith GD, "Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis", J Clin Pathol, 61, pp.487~493 (2008)
- Smouse JH, "EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer", Cancer Cytopathol, 117, pp.67~72 (2009)
- Travis WD, "Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift", J Thorac Oncol, 5, pp.411~414 (2010)
- Tsao MS, "Erlotinib in lung cancer - molecular and clinical predictors of outcome", N Engl J Med, 353, pp.133~144 (2005)
- West H, "Molecular analysis-based treatment strategies for the management of non-small cell lung cancer", J Thorac Oncol, 4, pp.S1029~S1039 (2009)
- Williams C, "High frequency of sequence alterations is due to formalin fixation of archival specimens", Am J Pathol, 155, pp.1467~1471 (1999)
- Yasufuku K, "Endobronchial ultrasound guided transbronchial needle aspiration for staging of lung cancer", Lung Cancer, 50, pp.347~354 (2005)